Revolution Medicines

An artists illustration of a KRAS G12C mutation in non-small cell lung cancer
Research

AACR: KRAS inhibitors pop in preclinical data debuts

Verastem Oncology, Quanta Therapeutics, Frontier Medicines and more showed off new preclinical data on drugs against the once-”undruggable” target.
Helen Floersh Apr 11, 2024 4:30am
unravel break rope tie fray fall apart thread string

The unraveling of EQRx's low-cost drug dream

Oct 5, 2023 10:47am
merge MA railway train tracks path together

EQRx's low cost drug dream ends in Revolution

Aug 1, 2023 8:49am
ship sail explore sea discovery adventure

Sanofi sets Revolution back, sending lead asset to the docks

Dec 8, 2022 7:14am
picture of a paraglider

Agios replaces CEO after recent FDA nod—Chutes & Ladders

Jul 15, 2022 9:30am
amgen

Amgen touts early combo data with Sanofi-backed KRAS partner

Jul 12, 2022 7:30pm